← United States · Coverage record
US · SEC FORM 4
Alto Neuroscience, Inc.
ANRO · NYSE · CIK 0001999480 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
8 Form 4 transaction lines observed in the same window
3 sales · 5 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-07-10 · Savitz Adam.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -32.3%
- 3M
- -5.4%
- 6M
- +14.4%
- 12M
- —
Volatility & liquidity
- Volatility
- 114.0%
- Beta
- —
- Avg daily value
- —
Valuation
- Market cap
- —
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- -41.8%
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-03 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 4,660,269
- Previous report
- 4,174,082
- Avg daily volume
- 718,187
- Days to cover
- 6.5
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-07-10 | Savitz Adam | Purchase (P) | Common Stock | 2,931 | USD 13.22 | USD 38,748 | SEC filing ↗ |
| 2024-07-09 | Savitz Adam | Purchase (P) | Common Stock | 12,069 | USD 12.60 | USD 152,085 | SEC filing ↗ |
| 2024-03-28 | Smith Nicholas Conrad | Purchase (P) | Common Stock | 6,150 | USD 16.36 | USD 100,628 | SEC filing ↗ |
| 2024-02-06 | Alpha Wave Global, LP; Alpha Wave Ventures GP, Ltd; Chimera Investment LLC; Lunate Holding RSC Ltd | Purchase (P) | Common Stock | 600,000 | USD 16.00 | USD 9,600,000 | SEC filing ↗ |
| 2024-02-06 | Smith Nicholas Conrad | Purchase (P) | Common Stock | 1,563 | USD 16.00 | USD 25,008 | SEC filing ↗ |
| 2024-02-06 | Savitz Adam | Purchase (P) | Common Stock | 17,000 | USD 16.00 | USD 272,000 | SEC filing ↗ |
| 2024-02-06 | Etkin Amit | Purchase (P) | Common Stock | 3,125 | USD 16.00 | USD 50,000 | SEC filing ↗ |
Form 4 evidence
10 transaction lines in the latest 365-day window; 32 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Smith Nicholas Conrad | Option exercise / conversion (M) | Common Stock | 55,000 | USD 2.32 | USD 127,600 | SEC filing ↗ |
| 2026-09-30 | Smith Nicholas Conrad | Sale (S) | Common Stock | 24,056 | USD 25.82 | USD 621,097 | SEC filing ↗ |
| 2026-09-30 | Smith Nicholas Conrad | Option exercise / conversion (M) | Common Stock | 24,056 | USD 2.35 | USD 56,532 | SEC filing ↗ |
Show recent Form 4 evidence (8 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Smith Nicholas Conrad | Option exercise / conversion (M) | Common Stock | 55,000 | USD 2.32 | USD 127,600 | SEC filing ↗ |
| 2026-09-30 | Smith Nicholas Conrad | Sale (S) | Common Stock | 24,056 | USD 25.82 | USD 621,097 | SEC filing ↗ |
| 2026-09-30 | Smith Nicholas Conrad | Option exercise / conversion (M) | Common Stock | 24,056 | USD 2.35 | USD 56,532 | SEC filing ↗ |
| 2026-09-29 | Smith Nicholas Conrad | Sale (S) | Common Stock | 110,830 | USD 26.58 | USD 2,946,150 | SEC filing ↗ |
| 2026-09-29 | Smith Nicholas Conrad | Option exercise / conversion (M) | Common Stock | 110,830 | USD 2.35 | USD 260,450 | SEC filing ↗ |
| 2026-05-14 | Etkin Amit | Gift (G) | Common Stock | 400,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-01 | Smith Nicholas Conrad | Tax withholding (F) | Common Stock | 2,806 | USD 19.69 | USD 55,250 | SEC filing ↗ |
| 2026-03-01 | Etkin Amit | Tax withholding (F) | Common Stock | 6,227 | USD 19.69 | USD 122,610 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ANRO |
| CIK | 0001999480 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | NYSE |
Data coverage
| Local Form 4 history | 32 transaction lines from 2024-02-06 to 2026-10-02 9 P purchase lines · 3 S sale lines · 20 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.